D N (Israel) Probability of Target Price Finishing Over Current Price

DNA -- Israel Stock  

ILS 23.90  0.10  0.42%

D N probability of target price tool provides mechanism to make assumptions about upside and downside potential of D N A Biomedical Solutions Ltd performance during a given time horizon utilizing its historical volatility. Please specify D N time horizon, a valid symbol (red box) and a target price (blue box) you would like D N odds to be computed. Additionally see D N Backtesting, D N Valuation, D N Correlation, D N Hype Analysis, D N Volatility, D N History as well as D N Performance.
Horizon     30 Days    Login   to change
Symbol:
Refresh Odds

D N Target Price Odds to finish over

Current PriceHorizonTarget PriceOdds to move above current price in 30 days
 23.90 30 days 23.90  ABOUT 38.9%
Based on normal probability distribution, the odds of D N to move above current price in 30 days from now is about 38.9% (This D N A Biomedical Solutions Ltd probability density function shows the probability of D N Stock to fall within a particular range of prices over 30 days) .
Assuming 30 trading days horizon, D N has beta of 0.1029 suggesting as returns on market go up, D N average returns are expected to increase less than the benchmark. However during bear market, the loss on holding D N A Biomedical Solutions Ltd will be expected to be much smaller as well. Additionally D N A Biomedical Solutions Ltd has a negative alpha implying that the risk taken by holding this equity is not justified. The company is significantly underperforming DOW
 D N Price Density 
 
      
Current Price   Target Price   
α
Alpha over DOW
=0.43
β
Beta against DOW=0.10
σ
Overall volatility
=8.79
Ir
Information ratio =0.19

D N Alerts

D N Alerts and Suggestions

D N A generates negative expected return over the last 30 days
D N A has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 0 in total debt. D N A Biomedical Solutions Ltd has Current Ratio of 0.18 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
This company reported revenue of . Net Loss for the year was (55.48 M).
DNA BIOMED SOLUT has accumulated about 1.52 M in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Additionally see D N Backtesting, D N Valuation, D N Correlation, D N Hype Analysis, D N Volatility, D N History as well as D N Performance. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com